Your SlideShare is downloading. ×
0
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Platelet function and dysfunction
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Platelet function and dysfunction

1,381

Published on

Published in: Technology, Health & Medicine
0 Comments
6 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,381
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
0
Comments
0
Likes
6
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Platelet Function and Dysfunction Paul Basciano MD October 24, 2013
  • 2. Outline • • • • • • • • Thrombopoiesis Platelet Structure Platelet Function Platelet Activation and Aggregation Biology Assessment of Platelet Function Inherited Disorders of Platelet Function Acquired Disorders of Platelet Function Treatment of Platelet Dysfunction
  • 3. PLATELET PRODUCTION, STRUCTURE, AND FUNCTION
  • 4. Thrombopoiesis • Humans produce 1x 10^11 platelets per day • Can increase 10-20 fold • Each megakaryocyte can produce 1000 platelets • The lifespan of a platelet is approximately 10 days • Platelet production from MK progenitors takes 4-7days • Most of this time is for the maturation of the megakaryocyte • Endomitosis • Cytoplasmic maturation
  • 5. Thrombopoietin • TPO is one of the key factors for platelet production • Produced constitutively by the liver (and kidney) • Circulating levels are determined by the megakaryocyte and platelet biomass • Low platelets more circulating TPO  increased platelet production • ITP is an exception to this • Normal platelets-> low TPO->low platelet production
  • 6. Thrombopoietin in Disease
  • 7. Platelet Structure • Alpha granules (many): PF4, vWF, fibronectin, thromboglobulin, FV, FXI, PS, TGFB, PDGF • Dense granules (3-8/cell): ADP, ATP, serotonin, pyrophosphate, calcium • Open canalicular system • Dense tubular system
  • 8. Platelet Functions • Primary hemostasis—the “platelet plug” • Secondary hemostasis—the coagulation cascade • Vasculature maintenance • Reservoir for soluble factors
  • 9. Collagen (especially Type I and III) Fibronectin Thrombospondin Laminin Bound-vWF
  • 10. Endothelial Damage Basement Membrane Exposures Platelet Adhesion Platelet Activation Phospholipid Exposure Coagulation Cascade (Secondary Hemostasis) Release of Soluble Factors Shape Change Integrin activation Activation of Other Platelets Platelet Aggregation
  • 11. Adhesion Phase: vWF GP Ib/IX/V Complex • Major receptor modulating interaction with vWF • GP Ibα is essential for arterial thrombus formation (Fab development) • No inherent signaling ability (no coupling to G proteins, no TK activity) • Found in lipid rafts in association with other GPs • Defects define Bernard Soulier Syndrome • Macrothrombocytopenia • No response to ristocetin on aggregometry
  • 12. AdhesionPhase: Collagen GP VI • Low-affinity but high impact for binding to collagen • Signals through Src kinases, as well as association with FcRg dimer which signals through ITAMs • Ab in development blocks thrombosis but does not prolong bleeding time GP Ia/IIa No specific human disease has been identified with a defect in either
  • 13. Platelet Activation: Granule Secretion and Integrin Activation • Initial binding leads to the release of agonists from the first-responding platelets which in turn leads to recruitment and activation of other near-by platelets • ADP • TxA2 • Epinephrine • Thrombin • All lead to the activation of GP IIb/IIIa (αIIb/β3 integrin) via inside-out signaling • Also lead to more granule secretion->feed forward mechanism • Activation of GPIIb/IIIa allows it to bind to fibrinogen (and vWF), to cross link platelets and allow the thrombus to form
  • 14. Platelet Activation: Outside-In and Inside-Out signaling
  • 15. Granule Secretion/GPCRs: ADP and P2Y1 and P2Y12 Receptors • Released from platelet dense granules and from RBCs • Interacts with the GPCRs • Leads to Ca elevation, TxA2 synthesis, protein phosphorylation, and shape change, granule secretion, activation of GPIIb/IIIa and aggregation • P2Y12 is more important • Few patients identified with dysfunction and bleeding diathesis • Major target of thienopyridine drugs • P2Y1 is necessary for full signaling and is a potential drug target
  • 16. GPCRs: Thromboxane A2 and Tpa receptor • The product of COX and TxA2 synthase enzymes using arachadonic acid (AA) as a precursor • Freely diffuses across plasma membrane • High activity during aggregation when platelets are closely apposed • Causes shape change, phospholipid hydrolysis, Ca mobilization, secretion, and aggregation via the TPa receptor • Aspirin inhibits COX-1 irreversibly
  • 17. GPCRs: Epinephrine and α2A Receptor • Weak agonist—cannot induce shape change or activate PLC • Reduces levels of cAMP within the platelet
  • 18. GPCRs: Thrombin and PAR receptors • Likely the most potent platelet activator • Acts via PAR-1 and PAR-4 (protease activated receptors) • The ligand is tethered to the receptor but hidden until it is cleaved Nature 407, 258-264(14 September 2000) • Also Ib/IX/V complex • Impaired thrombin responsiveness in BSS—Ib/IX possibly localizes thrombin to the PARs • PAR-1 is likely the primary mediator, but PAR4 is necessary for full activation • No clinical examples of PAR deficiencies have been described
  • 19. Adhesion Integrin Activation and Platelet Aggregation Secretion GPCRs activation Ca++, PKC Fibrinogen GP IIb/IIIa (αIIBβIII)
  • 20. ASSESSMENT OF PLATELET FUNCTION
  • 21. Evaluation of Platelet Function • • • • • Peripheral Blood Smear Bleeding Time PFA-100 Platelet aggregometry and secretion Thromboelastography
  • 22. Peripheral Blood Smear • Keys to look for: – Number of platelets – Size of platelets – Granulations within platelets – WBC inclusions
  • 23. Bleeding Time • Controversial, and mainly abandoned • Invasive, difficult to standardize • Requires dedicated technician to perform test over a relatively long period of time on one patient
  • 24. PFA-100 Epi or ADP collagen collagen • Rapid, automated, general assessment of platelet and overall hemostatic function – Replacing bleeding time • Citrated whole blood passed through aperture and time to closure with platelet plug is measured – Collagen with either epinephrine or ADP • High negative predictive value; low specificity
  • 25. PFA-100 • Influenced by many factors: – Hematocrit – Platelet count – Blood group – Timing and processing
  • 26. Platelet Aggregometry • Usually performed on platelet-rich plasma • Measures transmission of light through the solution full of platelets – As platelets aggregate, light transmission increases • Uses a panel of agonists to determine specific defect • Not well-standardized
  • 27. Aggregometry • Weak agonists: – ADP and epinephrine: biphasic platelet aggregation • Strong agonists – Collagen, TRAP (thrombin), arachadonic acid TXA2 • (Ristocetin: Agglutination) • Can also measure secretion of ATP and ADP
  • 28. SPECIFIC PLATELET DISORDERS
  • 29. Inherited Platelet Dysfunction
  • 30. Bernard-Soulier Syndrome • • • • • • Reduced/lack of GP Ib/IX Rare, autosomal recessive Moderate thrombocytopenia Large platelets Prolonged bleeding time Lack of response to ristocetin on platelet aggregometry (agglutination) – All other agonists are normal • ITP vs BSS • Can diagnose via flow cytometry
  • 31. Glanzmann Thombasthenia • Qualitative and/or quantitative abnormality of GP IIb/IIIa • More severe mucocutaneous bleeding than other platelet disorders • Rare, autosomal recessive • No aggregation response to any agonists except ristocetin • Normal secretion to thrombin, but reduced to weak agonists • Can diagnose via flow cytometry
  • 32. Storage Pool Disorders: Dense Granules • 3-8 dense granules per platelet; will not see problems on light microscopy • Contain ADP, ATP, serotonin, Ca, pyrophosphate • Moderate bleeding diathesis • Second wave of aggregation to ADP and Epi is lost • Reduced collagen response • Seen in association with Hermansky-Pudlak, ChediakHigashi, and Wiskott Aldrich, TAR, and Griscelli syndromes
  • 33. Hermansky-Pudlak • Rare autosomal disorder • Largest concentration in Puerto Rico • Occulocutaneous albinism, congenital nystagmus, decreased visual acuity • Also granulomatous colitis and pulmonary fibrosis
  • 34. Chediak-Higashi • Occulocutaneous albinism • Immune deficiency • Cytotoxic T and NK cell dysfunction • Neurologic symptoms • Cytoplasmic inclusions • LYST gene on chromosome 1 ASH Image Bank
  • 35. Storage Pools Disorders: Alpha Granules • Gray platelet syndrome – – – – – Mild thrombocytopenia Macrothrombocytopenia Pale platelets on light microscopy Variable inheritance Variable aggregation patterns • • Response to ADP and epi normal Collage, thrombin, and ADP impaired – Splenomegaly, fibrosis • Quebec platelet disorder – Autosomal dominant – Delayed bleeding – Increased proteolysis of alpha granule proteins (elevated platelet urokinase type plasminogen activator) – Thrombocytopenia – Reduced aggregation with epinephrine
  • 36. Signal Transduction and Activation Abnormalities • Abnormalities for specific agonist receptors or abnormalities of the signal transduction cascade – G proteins, phospholipase C, calcium mobilization, pleckstrin phosphorylation, phospholipase C, PKD – Thromboxane synthesis
  • 37. MYH-9 abnormalities (May-Hegglin) • MYH-9 mutations (myosin heavy chain) • Macrothrombocytopenia • Most commonly described as MayHegglin; – Fechtner, Epstein, Sebastian Syndromes are all part of the same spectrum • Neutrophil inclusions (Dohle bodies) • Abnormalities in kidneys, ears, heart
  • 38. Wiskott-Aldrich • Characterized by moderate to severe thrombocytopenia, with small platelet volumes • Wide clinical variability: – susceptibility to infections associated with adaptive and innate immune deficiency – eczema – isolated thrombocytopenia – X-linked neutropenia (XLN) • Mutation is WASP—actin remodeling protein • Platelet volumes are usually 3.5-5fL (normal=710fL)
  • 39. Scott Syndrome • Defect in platelet pro-coagulant activity • Failure to move phosphatidylserine to the outer membrane • Normal bleeding time and normal platelet aggregation
  • 40. Bleeding disorder Low Platelet Count Small Platelets Large Platelets Normal Platelet Count, Normal Size Very Abnormal Aggregometry Normal Aggregometry Glanzmann Wiskott-Aldrich No Color Issues Bernard Soulier Scott Quebec Color Issues Pale Platelets Pale People Gray Platelet Normal Neutrophils Kind-of adapted from Williams Hematology, 7th Ed. Neutrophil Inclusions Hermansky-Pudlack Chediak-Higashi
  • 41. Acquired Platelet Defects
  • 42. Aspirin • Irreversibly inhibits COX-1 and leads to inhibition of thromboxane A2 production • The most common antithrombotic in use • Inhibition with low-dose is complete (50100mg) – Essential thrombocythemia • Major bleeding risk is approximately 1% per year • Other NSAIDs block COX-1 to a lesser degree
  • 43. Thienopyridines • Clopidogrel, ticlopidine, and prasagurel • Work (mainly? in part?) by blocking the ADP receptor • Multiple methods to asses effect: aggregometry, PFA-100 (ADP), Verify-Now – All have significant variability in detection of ‘resistance’ and questionable clinical utility
  • 44. GP IIb/IIIa inhibitors • Abciximab, eptifibatide, tirofiban • Complete thrombasthenic state (Glanzman’s thrombasthenia) • High incidence of bleeding complications • May also cause acute thrombocytopenia – – – – Rapid onset, 30min to one day Variable recovery May be severe May also induce platelet clumping/ pseudothrombocytopenia
  • 45. Other medications • Penicillins (especially high dose) – Onset 2-3d, lasts 3-10d after discontinuation • Cephalosporins • SSRIs
  • 46. ADP Epi Collagen Ristocetan Bernard Soulier Glanzmann Storage Pool/Secretion www.practical-hemostasis.com
  • 47. Aggregometry in Platelet Disorders Disorder Ristocetin ADP Epinephrine Arachadonic Acid Collagen Bernard Soulier --- +++ +++ +++ +++ Glanzmann +++ --- --- --- --- Storage Pool/Release Defect + Primary only Primary only ASA Primary only Clopidogrel --- Primary only ----- ---
  • 48. Treatment • DDAVP for mild bleeding diathesis, uremic • Platelet transfusions – Allo-immunization against absent GP receptors may occur • • • • Estrogens Amicar Novo7 (Esp. Glanzmann) TPO agents (Bernard Soulier, MYH-9, ?others)

×